Hims & Hers Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter revenue grew 49% year over year to $890 million, the second consecutive quarter of accelerating revenue growth; the reported figure excluded $18 million of deferred weight loss membership revenue to be recognized in the 4th quarter.
- Subscribers grew 13% year over year to 2.8 million but declined sequentially by 100,000, reflecting measured marketing spend in domestic weight loss and international brand migrations.
- Domestic revenue increased 21% year over year to $657 million, compared with 16% growth in the 2nd quarter.
- International revenue more than 4x year over year to $233 million, including approximately $135 million from Eucalyptus; the remaining international portfolio grew nearly 80%.
- GAAP net income was a loss of $33 million; adjusted EBITDA grew 37% quarter over quarter to $82 million, a 9% margin, and gross margin was 57%, down approximately 7 points quarter over quarter.
- Cash flow from operations was $65 million and free cash flow was $26 million in the 3rd quarter; cash and investments totaled over $710 million at quarter end.
- Management said the AI-native experience reached 70% of weight loss subscribers at quarter end, with customers who had access sending 4 times as many messages; the experience was available to the large majority of weight loss customers across Hims and Hers by quarter end.
- Testosterone offerings expanded to injectable and oral TRT, and the company said it plans to launch Peptides Plus later this month.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to the Hims & Hers Health Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Bill Newby, Director of Investor Relations.
Bill, please go ahead. Good afternoon, everyone, and welcome to the Hims & Hers Health Third Quarter 2026 Earnings Call.
On the call with me today is Andrew Dudum, our Co-Founder and Chief Executive Officer, Yemi Okupe, our Chief Financial Officer, and Mo Elshenawy, our Chief Technology Officer. Before I hand it over to Andrew, I need to remind you of legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on, among other things, our current market, competitors, and regulatory expectations, and are subject to risks and uncertainties that could cause actual results to vary materially. We take no obligation to update publicly any forward-looking statement after this call, whether as a result of new information, future events, changes in assumptions, or otherwise.
The risks, uncertainties, and other factors that could cause actual results to differ from our forward-looking statements are described in our earnings release and SEC filings. Please see our recent earnings release and most recently filed 10-K and 10-Q reports for a discussion of these risk factors as they relate to forward-looking statements. In today's presentation, we also have certain non-GAAP financial measures. We refer you to the reconciliation tables to the most directly comparable GAAP financial measures contained in today's press release. You can find this information as well as a link to today's webcast at investors.hims.com. After the call, this webcast will be archived on the website for 12 months. With that, I'll turn the call over to Andrew.
Thanks, Bill. Good afternoon, everyone, and thank you for joining us. This was a quarter of real progress toward building a company that we believe has never existed before, an everyday digital health platform that tens of millions of people rely on, not for a single treatment, but for the whole of how they take care of themselves. Before we turn it to the quarter, I want to spend a few minutes on the thesis behind everything we're building, because it explains both the results you're seeing today and the decisions we're making for the years ahead. Our conviction is simple. In healthcare, whoever owns the customer relationship wins. That's easy to say and very hard to do. Most companies in our industry build around a treatment, a condition, or a moment in time. They capture a single transaction, but then lose the thread. Customers want something different. They want a place that knows them, stays with them, and grows with them as their needs change.
We are building that place, one platform to bring together the best clinical expertise, diagnostics, prescription medications, daily insights from wearables, supplements, and other tools that support how someone lives every day. What makes this possible is a business model we believe is unique in healthcare. We own brands that the customer trusts. We own the platform that connects customers with care. We own more than 1 million square feet of pharmacy, lab, and compounding infrastructure that fulfills that care. We own the AI technology that connects all of it into a single continuous thread.
Because our relationship is directly with the customer, every improvement we make in one specialty strengthens all of them. Every efficiency we unlock in our infrastructure can be returned to the customer as a lower price or more comprehensive care. That is a multiplier model, not a transactional one, and it is the reason we believe the value in this industry will accrue to us and our ecosystem partners over time. The foundation is already substantial. Revenue growth accelerated to nearly 50% this quarter. Nearly 3 million people across four continents rely on us to access care. That trust has made us a valuable partner to global pharmaceutical leaders like Novo and Lilly, and it positions us to keep bringing the most innovative treatments to our customers as they come to market.
We have also welcomed Andrew Huberman, the world-renowned neuroscientist and tenured Stanford professor, to our board and as a scientific and brand marketing advisor. Our own pharmacy and lab infrastructure continues to scale, driving efficiency across every specialty. Paired with an AI-native experience that can support customers around the clock, that infrastructure positions us to launch treatments of increasing complexity, including testosterone replacement therapy this quarter and our Peptides+ offering later this month. Our long-term strategy flows directly from this thesis, and it rests on three critical commitments. First, win metabolic health in the U.S. and around the world. Second, lead the major markets globally. Third, be at the forefront of category expansion so that the platform is always growing in what it can do for the people who trust it.
Each of these reinforces the other, and together, they describe how Hims & Hers becomes the global destination for consumer health. We are investing aggressively against all three, because this opportunity is growing quickly, and we believe it will become more valuable every quarter. Every decision we made this quarter served those commitments, including how and when we put our marketing dollars to work. The weight loss business has undergone structural changes in the last few quarters, and we have intentionally pulled back on marketing spend in order to execute on three things in advance of the new year. The first was to position ourselves to win the metabolic business. That means working with Lilly so we can offer a seamless experience across a full assortment of weight loss medicines.
It means working closely with Novo on expanding assortment and pricing options while preparing for the launch of CagriSema once it becomes available. It means developing innovative multi-month subscriptions that make it easier for customers to get access to medications at more accessible price points. The second was preparing to invest aggressively in our international markets. In key regions like the U.K., Germany, and Australia, we are consolidating our brands under Hims & Hers, and we will be redeploying marketing investment alongside pricing actions designed to win share in markets where we believe the revenue potential is substantial. The third was to create the flexibility to invest behind the new specialties and offerings we are bringing to the platform, both in the capabilities needed to deliver them and building awareness so customers know they are here as we enter 2027.
Each of these choices trades near-term subscriber growth for a stronger position in the years that follow. That is a trade we will make every time, and we will put our next wave of marketing investment to work ahead of the new year, when interest in weight loss reaches its annual peak, and when the broader assortment, the more connected care experience, and the greater ability to serve our customers' full set of needs are in place. Let me take each commitment in turn. Metabolic health comes first for a reason. It is the entry point. It is where people most often first seek help, and when we earn a strong, trusted relationship there, we earn the right to care for them in other areas that matter to them. That is what makes it the foundation of the customer relationship rather than simply our largest category.
It is also one of the largest markets in healthcare, and we believe we are still in the earliest days of adoption. It is also a very profitable business over the long term, and we do not have to speculate about that. Our international markets are ahead of the U.S. in the arrival of lower prices and generics, and they show us where this category is going. Our teams abroad have years of experience working with Novo and Lilly, and the pattern is consistent. As prices come down and treatment options expand, more customers come to the platform, they stay longer, and our margins strengthen. Economics often improve as categories mature, and we are building the U.S. business with that in mind. It is the same cycle we have seen in sexual health and hair.
Maturation brings more people into care, and the strength of our platform is that customers can access all of it in one place, with a care team that helps them find what is right for them. In the U.S., our collaboration with Novo reignited growth in our weight loss specialty. We are now deepening that partnership and plan to expand assortment and pricing options to make it easier for customers to start and stick with their treatment. We are also preparing for the launch of CagriSema once available. Through our recently announced agreement, we will expand access to Lilly's GLP-1 medications, Zepbound and Foundayo, offering customers a seamless experience across the full assortment of their weight loss medicines. We are thrilled to be working with Lilly in this new capacity and look forward to our continued collaboration to benefit patients.
In addition, ahead of the new year, we are preparing to launch flexible multi-month subscriptions across our assortment, making it easier for customers to commit to a course of treatment and address their health goals at a price that works for them. We will continue to prioritize partnerships across the industry, with the goal that whenever an innovative therapy reaches the market, our customers can access it here. That assortment will sit alongside an AI-native experience that will soon be available to nearly every weight loss customer on our platform. As Mo Elshenawy will describe, this experience is driving higher engagement across the specialty, making it easier for customers to adhere to their treatment plan, manage side effects, and reach a provider quickly when something needs to change. That engagement is how the entry point becomes a relationship. The better we know our customers, the more we can do for them.
Our success in the U.S. gives us confidence to execute on our second priority, leading internationally, where digital health is still maturing as a trusted option. We intend for Hims & Hers to become synonymous with consumer-centric healthcare, not only in the U.S., but in every one of the world's major markets. International revenue is on track to eclipse a $1 billion revenue run rate in 2027, as customers across these markets embrace a comprehensive digital health experience that we believe has never been available to them locally. That is why we are directing more investment toward the U.K., Germany, and Australia. We believe these markets carry substantial revenue potential, and we intend to act with conviction in establishing market leadership while the category is still being defined. We don't believe anyone operating these markets has our combination of breadth, scale, infrastructure, and expertise.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
